Cancer-Relevant Genetic Findings

1. Executive summary

Current clinical status: post radical prostatectomy with biochemical recurrence. The prostate has been surgically removed; pathology revealed more disease than anticipated. PSA at 0.35 ng/mL post-operatively meets the AUA / NCCN definition of biochemical recurrence (PSA ≥ 0.2 ng/mL with confirmation, or rising PSA on consecutive draws). The standard-of-care next step is salvage radiation therapy to the prostate bed (with or without pelvic nodal coverage and with or without short-course androgen-deprivation therapy depending on risk stratification). PSMA-PET is scheduled to localize the recurrent focus prior to radiation planning.

The genetic data in this document is therefore most relevant to: (a) refining the salvage-radiation plan via Decipher tumor genomic scoring on the existing prostatectomy tissue; (b) identifying germline variants that would change systemic-therapy options if the disease progresses beyond the current biochemical-recurrence stage; and (c) family cascade testing for first-degree relatives.

A consumer-grade direct-to-consumer (MyHeritage) microarray was run on this patient and reviewed for cancer-relevant variants. The chip's coverage of clinically actionable cancer variants is limited: common tagging SNPs are well-represented, but most rare pathogenic variants (frameshift, splice-site, large indel) in the major cancer-predisposition genes (BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13, and the MMR genes) are NOT probed by this chip and cannot be ruled in or out from this data.

Within the chip's coverage:

• No common pathogenic variants in CHEK2, MLH1, BRCA1 (rs1799950), or 9p21 haplotype suggesting elevated cancer-predisposition burden.
• Polygenic prostate-cancer risk score on tested loci is ~30% — lower than expected for a man with diagnosed PCa. This is itself a clinical clue: the disease may be driven by a rare germline pathogenic variant or somatic events not visible to this chip.
• One PCa risk locus (17p12, rs4054823) is homozygous-risk — modest contribution only (per-allele OR ≈ 1.2).
• Pharmacogenomic profile relevant to upcoming therapy is unremarkable: normal CYP2C19, typical OPRM1 (opioid response), CYP3A5*3/*3 (common Caucasian non-expresser pattern).

2. Methodology and limitations

The source data is a MyHeritage microarray (consumer-grade, Illumina-based), which genotypes approximately 720,000 single-nucleotide polymorphisms (SNPs) selected primarily for population-genetics and ancestry research. Coverage is excellent for common variants (minor allele frequency ≥ 1%) but is sparse to absent for rare variants and intentionally avoids most clinically pathogenic frameshift / nonsense / splice-site variants.

What this chip can detect

• Common population variants (tagging SNPs) in cancer-related genes — useful for polygenic risk scoring
• A small number of high-frequency pathogenic alleles where the chip happens to probe them (e.g., HFE C282Y, common APOE haplotypes — not relevant here)

What this chip cannot detect

• Founder pathogenic variants in BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) — not on this chip
• BRCA2 K3326X stopgain — not on this chip
• CHEK2 1100delC truncation — not on this chip
• HOXB13 G84E (rs138213197) — the principal hereditary prostate-cancer marker. Not on this chip. Cannot be ruled out without targeted sequencing.
• The vast majority of pathogenic variants in ATM, PALB2, and the MMR genes (MLH1, MSH2, MSH6, PMS2)
• Copy-number variants and structural rearrangements

A clinical-grade germline panel (e.g., Color Health, Invitae, Ambry CancerNext, Myriad MyRisk) sequences the relevant exons directly and detects the actionable variants this chip misses. This is the appropriate next test.

3. Direct findings — chip coverage of high-priority genes

Hereditary prostate cancer

PARP-inhibitor eligibility (DNA repair / homologous recombination)

Clinical relevance, post-prostatectomy. At the current stage (biochemical recurrence post-RP), the immediate treatment driver is salvage radiation, not systemic therapy — so a pathogenic variant in these genes does not change today's plan. However, identifying a pathogenic variant now matters because: (i) if the disease progresses to metastatic castration-resistant prostate cancer (mCRPC) in the future, BRCA1/2 / ATM / CHEK2 / PALB2 carriers qualify for PARP inhibitors (olaparib, rucaparib) under current FDA labeling, materially expanding treatment options at that stage; (ii) it informs family-cascade testing for the patient's four children today, regardless of his own treatment course.

Lynch syndrome / mismatch repair (immunotherapy eligibility)

Clinical relevance. A pathogenic Lynch-syndrome variant would qualify this patient for pembrolizumab or nivolumab if the tumor is microsatellite-instability-high (MSI-H), per FDA tissue-agnostic approval. MSI status can also be assessed directly on tumor tissue.

Tumor suppressor / context

4. Polygenic prostate-cancer risk — GWAS loci on chip

The chip carries a subset of the ~170 known prostate-cancer GWAS risk loci. We scored the loci it does cover. Each locus contributes a small per-allele odds ratio (typically OR 1.1–1.3); the cumulative effect of common variants is what polygenic risk scores quantify.

Total: 3 risk alleles out of 10 possible (30%) on tested loci. For comparison, men diagnosed with sporadic prostate cancer typically carry 50–65% of available risk alleles in the loci that overlap this chip. The lower-than-expected polygenic burden raises the prior probability of a rare germline driver, an environmental or somatic driver, or a tumor genomic profile that would be productively assessed by tumor-tissue testing.

5. Treatment-relevant findings

The chip yields three actionable insights for the treatment course ahead, plus important gaps the medical team should know about. Most relevant of all: the chip does not resolve the question of inherited DNA-repair-gene status that would predict radiation response — the most immediate treatment Walter faces.

Pharmacogenomics — what the chip read

Pharmacogenomics — what the chip missed (recommend testing)

A clinical PGx panel (e.g., GeneSight, Genelex YouScript) is the appropriate test if any of these drug classes become relevant during treatment. Many oncology centers can order one ad-hoc.

Radiation-response genetics — the most relevant gap

Salvage radiation is the planned treatment. Radiation kills cancer cells primarily by inducing DNA double-strand breaks and overwhelming the cell's DNA-damage-response machinery. The genes that handle that machinery — ATM, BRCA1, BRCA2, CHEK2, PALB2 — therefore directly affect both:

• Tumor radiosensitivity (cells with defective DNA repair are more killable by radiation — potentially better treatment response).
• Normal-tissue toxicity (germline carriers of pathogenic DNA-repair variants can experience higher late-radiation effects in surrounding tissue — bowel, bladder, neurovascular bundles in the prostate-bed field).

Specifically for salvage radiation in BCR after prostatectomy, an inherited ATM heterozygous pathogenic variant would meaningfully shift the conversation: the radiation oncologist may consider modified fractionation (smaller dose per fraction, longer course) or proton therapy to spare normal tissue. This data is not on the MyHeritage chip. The clinical germline panel discussed in §6 is the resolution path.

If treatment progresses to systemic therapy

Should the disease ever progress beyond biochemical recurrence to require systemic therapy, the genetic findings (or lack thereof) on this chip become more immediately relevant:

• Abiraterone (Zytiga) — metabolized primarily by CYP3A4 with secondary CYP2D6 contribution. Walter's CYP3A5 non-expresser status is consistent with normal abiraterone clearance. CYP2D6 status (not on chip) would be the missing piece; reasonable to test before initiation.
• Enzalutamide (Xtandi) — CYP2C8 and CYP3A4 substrate. No data from this chip; PGx panel recommended before initiation.
• Docetaxel — CYP3A4 substrate. CYP3A5 status (we have) is largely irrelevant; CYP3A4 variants (not on chip) are more determinative.
• Olaparib / rucaparib (PARP inhibitors) — CYP3A4-cleared. Plus the eligibility-conferring germline finding (BRCA/ATM/CHEK2/PALB2) is itself absent from this chip and requires the clinical panel.
• Leuprolide / goserelin (LHRH agonists) — peptide drugs, not CYP-metabolized; no PGx considerations.

6. Recommended next steps

7. Family screening implications

If the recommended clinical germline panel returns a pathogenic variant, cascade testing of first-degree relatives is warranted. The patient has four children (three sons, one daughter, all adult). Specifically:

Cascade testing of relatives is independent of the patient's own treatment status and remains highly relevant despite the prostate having been surgically removed — because germline variants are inherited and affect all downstream cancer risk for the children, not only their prostate-cancer risk.

• HOXB13 G84E carrier: the three sons should begin PSA screening at age 40 and continue annually, regardless of standard age-based guidelines. (Walter himself no longer has a prostate; this is purely a family-screening consideration.)
• BRCA1 / BRCA2 carrier: sons enter a higher-risk PCa screening protocol; the daughter should be referred to high-risk breast/ovarian cancer surveillance (MRI plus mammography typically beginning at age 30 or 5–10 years before earliest family diagnosis). Walter himself, post-prostatectomy, retains elevated risk for BRCA-associated secondary cancers (pancreatic, breast in men) that may warrant additional surveillance.
• ATM, CHEK2, PALB2 carrier: family members may benefit from earlier and more intensive cancer screening per NCCN guidelines (breast for the daughter; PCa screening adjustments for the sons).
• Lynch syndrome (MMR pathogenic variant): first-degree relatives require colonoscopy beginning at age 25 (or 5–10 years before earliest family diagnosis), with endometrial and other surveillance per Lynch protocols. Walter himself would benefit from Lynch-protocol colonoscopy and dermatology follow-up regardless of prostate status.

Cascade testing is typically priced at the same per-test rate as the index test (Color $249/person; Invitae often free for first-degree relatives of a positive proband under their family-testing program).